ER POSITIVE BREAST CANCER
Clinical trials for ER POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ER POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for ER POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for advanced breast cancer: phase 3 trial of OP-1250 launches
Disease control Recruiting nowThis study tests a new drug called OP-1250 (palazestrant) against standard treatments (fulvestrant or an aromatase inhibitor) in 510 people with a common type of advanced breast cancer (ER+, HER2-). Participants must have already tried hormone therapy plus a CDK4/6 inhibitor. The…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 02:23 UTC
-
New hope for advanced breast cancer: phase 3 trial launches
Disease control Recruiting nowThis study tests a new drug, palazestrant, combined with ribociclib against the standard letrozole with ribociclib for people with ER+, HER2- advanced breast cancer that has not been treated before. About 1,000 adults with locally advanced or metastatic breast cancer will take pa…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 02:21 UTC
-
Promising combo aims to slow advanced breast cancer
Disease control Recruiting nowThis study tests whether adding everolimus to elacestrant can help people with a certain type of advanced breast cancer (ER+/HER2-, with an ESR1 mutation) live longer without their cancer growing. About 240 adults whose cancer has worsened after standard treatments will receive e…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: MedSIR • Aim: Disease control
Last updated May 26, 2026 02:11 UTC
-
New hope for advanced breast cancer patients in early drug trial
Disease control Recruiting nowThis study tests a new drug called OP-1250 (Palazestrant) combined with other targeted therapies in people with advanced or metastatic ER-positive, HER2-negative breast cancer. About 190 adults will receive one of four drug combinations to find the safest dose and understand side…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 19, 2026 12:00 UTC
-
New hope for breast cancer patients after first treatment fails
Disease control Recruiting nowThis study is for people with a certain type of advanced breast cancer (ER-positive, HER2-negative) that has stopped responding to a common first treatment. The trial will test a combination of two drugs, fulvestrant and abemaciclib, after a short break from the previous treatmen…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated May 18, 2026 12:12 UTC
-
New drug cocktail aims to wipe out breast cancer before surgery
Disease control Recruiting nowThis study tests whether giving a combination of three drugs (neratinib, an aromatase inhibitor, and trastuzumab) for 24 weeks before surgery can eliminate all signs of cancer in the breast tissue of people with ER-positive, HER2-positive breast cancer. About 30 postmenopausal wo…
Matched conditions: ER POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Ruth O'Regan • Aim: Disease control
Last updated May 15, 2026 11:54 UTC